Cargando…
A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion
BACKGROUND: Although intravenous immunoglobulin (IVIG) therapy is generally safe and well tolerated, adverse reactions (ARs) do occur. The majority of these ARs are mild and transient. Risk factors for ARs associate with IVIG infusions are not well established. This study investigated possible risk...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479165/ https://www.ncbi.nlm.nih.gov/pubmed/34603326 http://dx.doi.org/10.3389/fimmu.2021.740517 |
_version_ | 1784576191572738048 |
---|---|
author | Kato, Hidefumi Hayashi, Megumi Ohashi, Wataru Yamaguchi, Takamasa Tanaka, Satomi Kozono, Ayumi Gao, Siqiang Katai, Akiko Niwa, Reiko Matsuo, Tomohito Ishiyama, Kazuki Ando, Takanori Ogawa, Mika Nakayama, Takayuki |
author_facet | Kato, Hidefumi Hayashi, Megumi Ohashi, Wataru Yamaguchi, Takamasa Tanaka, Satomi Kozono, Ayumi Gao, Siqiang Katai, Akiko Niwa, Reiko Matsuo, Tomohito Ishiyama, Kazuki Ando, Takanori Ogawa, Mika Nakayama, Takayuki |
author_sort | Kato, Hidefumi |
collection | PubMed |
description | BACKGROUND: Although intravenous immunoglobulin (IVIG) therapy is generally safe and well tolerated, adverse reactions (ARs) do occur. The majority of these ARs are mild and transient. Risk factors for ARs associate with IVIG infusions are not well established. This study investigated possible risk factors influencing the occurrence of IVIG-associated ARs. STUDY DESIGN AND METHODS: This was a retrospective observational analysis of data accumulated over 5 years, including patient demographics, clinical condition, IVIG dosing regimens, number of IVIG infusions, and any ARs. RESULTS: ARs were associated with IVIG in 4.9% of patients and 2.5% of infusions. By univariate analyses, ARs correlated with female sex, adult age, high dose IVIG, and autoimmune disease. Multivariate logistic regression identified three statistically significant of risk factors: on a per-patient basis, being female (p=0.0018), having neuromuscular disease (p=0.0002), and receiving higher doses of IVIG per patient body weight (p<0.001), on a per-infusion basis, being female (p < 0.001), being adolescents to middle age (p < 0.001), and having neuromuscular disease (p < 0.001). CONCLUSION: Neuromuscular disease emerged as one of the significant factors for ARs to IVIG. |
format | Online Article Text |
id | pubmed-8479165 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84791652021-09-30 A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion Kato, Hidefumi Hayashi, Megumi Ohashi, Wataru Yamaguchi, Takamasa Tanaka, Satomi Kozono, Ayumi Gao, Siqiang Katai, Akiko Niwa, Reiko Matsuo, Tomohito Ishiyama, Kazuki Ando, Takanori Ogawa, Mika Nakayama, Takayuki Front Immunol Immunology BACKGROUND: Although intravenous immunoglobulin (IVIG) therapy is generally safe and well tolerated, adverse reactions (ARs) do occur. The majority of these ARs are mild and transient. Risk factors for ARs associate with IVIG infusions are not well established. This study investigated possible risk factors influencing the occurrence of IVIG-associated ARs. STUDY DESIGN AND METHODS: This was a retrospective observational analysis of data accumulated over 5 years, including patient demographics, clinical condition, IVIG dosing regimens, number of IVIG infusions, and any ARs. RESULTS: ARs were associated with IVIG in 4.9% of patients and 2.5% of infusions. By univariate analyses, ARs correlated with female sex, adult age, high dose IVIG, and autoimmune disease. Multivariate logistic regression identified three statistically significant of risk factors: on a per-patient basis, being female (p=0.0018), having neuromuscular disease (p=0.0002), and receiving higher doses of IVIG per patient body weight (p<0.001), on a per-infusion basis, being female (p < 0.001), being adolescents to middle age (p < 0.001), and having neuromuscular disease (p < 0.001). CONCLUSION: Neuromuscular disease emerged as one of the significant factors for ARs to IVIG. Frontiers Media S.A. 2021-09-15 /pmc/articles/PMC8479165/ /pubmed/34603326 http://dx.doi.org/10.3389/fimmu.2021.740517 Text en Copyright © 2021 Kato, Hayashi, Ohashi, Yamaguchi, Tanaka, Kozono, Gao, Katai, Niwa, Matsuo, Ishiyama, Ando, Ogawa and Nakayama https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Kato, Hidefumi Hayashi, Megumi Ohashi, Wataru Yamaguchi, Takamasa Tanaka, Satomi Kozono, Ayumi Gao, Siqiang Katai, Akiko Niwa, Reiko Matsuo, Tomohito Ishiyama, Kazuki Ando, Takanori Ogawa, Mika Nakayama, Takayuki A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion |
title | A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion |
title_full | A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion |
title_fullStr | A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion |
title_full_unstemmed | A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion |
title_short | A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion |
title_sort | retrospective observational study of adverse reactions associated with intravenous immunoglobulin infusion |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479165/ https://www.ncbi.nlm.nih.gov/pubmed/34603326 http://dx.doi.org/10.3389/fimmu.2021.740517 |
work_keys_str_mv | AT katohidefumi aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion AT hayashimegumi aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion AT ohashiwataru aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion AT yamaguchitakamasa aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion AT tanakasatomi aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion AT kozonoayumi aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion AT gaosiqiang aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion AT kataiakiko aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion AT niwareiko aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion AT matsuotomohito aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion AT ishiyamakazuki aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion AT andotakanori aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion AT ogawamika aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion AT nakayamatakayuki aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion AT katohidefumi retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion AT hayashimegumi retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion AT ohashiwataru retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion AT yamaguchitakamasa retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion AT tanakasatomi retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion AT kozonoayumi retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion AT gaosiqiang retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion AT kataiakiko retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion AT niwareiko retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion AT matsuotomohito retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion AT ishiyamakazuki retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion AT andotakanori retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion AT ogawamika retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion AT nakayamatakayuki retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion |